Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.IMUX · Entity 6306 | Director | July 05, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date July 05, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.80 · Expires 2036-07-05 | Direct | 25,370 |
Reported balance
After 2026-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-05 · Grant · Acquired 25,370 · Balance 25,370 F1: The option vests in monthly increments over a period of one year from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in monthly increments over a period of one year from the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2026 Filed Jul 7, 2026 20:05 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 25,370 | $0.00 Strike: $14.80 | $0.00 |
DisclosureSEC source: 0001193805-26-000929 · e665632_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,370 Underlying: Common Stock · 25,370 shares Expires 2036-07-05 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 20:32 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 25,370 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193805-26-000888 · e665608_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,370 Underlying: Common Stock · 25,370 shares Expires 2036-03-27 F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. F2 · derivative.exercise_date: The option is fully vested as of March 27, 2026. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 20:07 UTC | IMMUNIC, INC. IMUX · Entity 6306 | PurchaseCommon Stock | 30,000 | $0.76 | $22,800.00 |
DisclosureSEC source: 0001193805-25-000800 · e664594_4-jorg.xml · nonDerivative · entry 2 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F3 · price: The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 5, 2025 (at Euro 1.00 = U.S. dollar 1.1477). Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001193805-25-000838 · e664607_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:07 UTC | IMMUNIC, INC. IMUX · Entity 6306 | PurchaseCommon Stock | 70,000 | $0.77 | $53,900.00 |
DisclosureSEC source: 0001193805-25-000800 · e664594_4-jorg.xml · nonDerivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7661 to $0.7730. The Reporting Person (RP) undertakes to provide to the Issuer, any securityholder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price. F2 · price: The purchases were made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384). Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 20:08 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001193805-24-000788 · e663707_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 02:50 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 64,959 | Not disclosed Strike: $1.72 | Not disclosed |
DisclosureSEC source: 0001193805-24-000319 · e619333_4-joerg.xml · derivative · entry 5 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,959 Underlying: Common Stock · 64,959 shares Expires not disclosed F1 · derivative.exercise_price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · derivative.expiration_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 02:50 UTC | IMMUNIC, INC. IMUX · Entity 6306 | Disposition to issuerStock Option · Derivative | 10,000 | Not disclosed Strike: $3.40 | Not disclosed |
DisclosureSEC source: 0001193805-24-000319 · e619333_4-joerg.xml · derivative · entry 4 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-06-15 F1 · derivative.exercise_price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 02:50 UTC | IMMUNIC, INC. IMUX · Entity 6306 | Disposition to issuerStock Option · Derivative | 10,000 | Not disclosed Strike: $14.77 | Not disclosed |
DisclosureSEC source: 0001193805-24-000319 · e619333_4-joerg.xml · derivative · entry 3 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 02:50 UTC | IMMUNIC, INC. IMUX · Entity 6306 | Disposition to issuerStock Option · Derivative | 15,000 | Not disclosed Strike: $12.30 | Not disclosed |
DisclosureSEC source: 0001193805-24-000319 · e619333_4-joerg.xml · derivative · entry 2 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2030-07-01 F1 · derivative.exercise_price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 02:50 UTC | IMMUNIC, INC. IMUX · Entity 6306 | Disposition to issuerStock Option · Derivative | 29,959 | Not disclosed Strike: $13.63 | Not disclosed |
DisclosureSEC source: 0001193805-24-000319 · e619333_4-joerg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,959 shares Expires 2029-07-22 F1 · derivative.exercise_price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 20:38 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 16,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001193805-23-000917 · e618743_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 21:06 UTC | IMMUNIC, INC. IMUX · Entity 6306 | PurchaseCommon Stock | 47,000 | $1.26 | $59,032.00 |
DisclosureSEC source: 0001193805-22-001729 · e618126_4-jorg.xml · nonDerivative · entry 2 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $1.22 to $1.28 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought by him at each separate price on December 14, 2022. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:06 UTC | IMMUNIC, INC. IMUX · Entity 6306 | PurchaseCommon Stock | 35,000 | $1.25 | $43,610.00 |
DisclosureSEC source: 0001193805-22-001729 · e618126_4-jorg.xml · nonDerivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $1.23 to $1.28 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought by him at each separate price on December 13, 2022. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 21:05 UTC | IMMUNIC, INC. IMUX · Entity 6306 | PurchaseCommon Stock | 18,000 | $1.39 | $25,020.00 |
DisclosureSEC source: 0001193805-22-001609 · e618059_4-jorg.xml · nonDerivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Read SEC document |
| June 15, 2022 Filed Jun 18, 2022 01:33 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001193805-22-000970 · e621757_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:01 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001193805-21-000865 · e620709_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:17 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000797 · e619750_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 21:48 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 29,959 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0001193805-19-000672 · e618566_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 Underlying: Common Stock · 29,959 shares Expires 2029-07-22 F1 · derivative.exercise_date: 9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.